Clinical Trial Update: Lanadelumab in Long-term Prophylaxis of Acquired Angioedema [Phase 4]

View source ↗

Summary

A Phase 4 trial is evaluating lanadelumab for long-term prophylaxis of acquired angioedema, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Angioedema

Drugs mentioned

• Lanadelumab (lanadelumab)

Snippet

Sponsor: Bernstein Clinical Research Center | Conditions: Angioedema | Phase 4 | Status: RECRUITING